Drug repurposing a compelling cancer strategy with bottomless opportunities: Recent advancements in computational methods and molecular mechanisms

• Published in: Indian journal of pharmacology 2023-09, Vol.55 (5), p.322-331
• Main Authors: Dash, Rasmita, Yadav, Madhulika, Biswal, Jyotirmaya, Samanta, Shrabani, Sharma, Tripti, Mohapatra, Sujata
• Format: Article
• Language: English
• Subjects: Antineoplastic Agents - pharmacology; Antineoplastic Agents - therapeutic use; Cancer; Cancer therapies; Clinical outcomes; Drug Discovery; Drug efficacy; Drug Repositioning - methods; Drug therapy; Drugs; Health aspects; Humans; Neoplasms - drug therapy; Oncology; Pharmacology, Experimental; R&D; Research & development; Review; Targeted cancer therapy
• ISSN: 0253-7613; 1998-3751
• DOI: 10.4103/ijp.ijp_626_22

Drug discovery has customarily focused on a de novo design approach, which is extremely expensive and takes several years to evolve before reaching the market. Discovering novel therapeutic benefits for the current drugs could contribute to new treatment alternatives for individuals with complex medical demands that are safe, inexpensive, and timely. In this consequence, when pharmaceutically yield and oncology drug efficacy appear to have hit a stalemate, drug repurposing is a fascinating method for improving cancer treatment. This review gathered about how in silico drug repurposing offers the opportunity to quickly increase the anticancer drug arsenal and, more importantly, overcome some of the limits of existing cancer therapies against both old and new therapeutic targets in oncology. The ancient nononcology compounds' innovative potential targets and important signaling pathways in cancer therapy are also discussed. This review also includes many plant-derived chemical compounds that have shown potential anticancer properties in recent years. Here, we have also tried to bring the spotlight on the new mechanisms to support clinical research, which may become increasingly essential in the future; at the same time, the unsolved or failed clinical trial study should be reinvestigated further based on the techniques and information provided. These encouraging findings, combined together, will through new insight on repurposing more non-oncology drugs for the treatment of cancer.